Evotec/Haplogen collaborate to develop drugs for viral diseases
Evotec and Haplogen have signed a collaboration agreement to discover and develop small molecules against viral infectious diseases. Under the agreement, Haplogen and Evotec will co-develop drugs against a human protein that is essential for pathogenic viruses to infect their host cell. This protein was discovered by Haplogen's powerful proprietary technology to identify host factors for infectious human pathogens. Evotec will further develop Haplogen's lead compounds and apply its drug-discovery platform to find additional small-molecule inhibitors. Terms of the partnership were not disclosed.